Torii

Myovant’s fibroids drug clears phase 3 trial, but shares sink

In Myovant’s favour is that relugolix is also already on the market in Japan, where it is sold by Takeda.

Lilly scores FDA okay for Cyramza in liver cancer

Lilly has also filed for approval of Cyramza in AFP-high HCC in the EU and Japan.

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

In the EU and Japan, approval of the drug is pending, following acceptance of regulatory filings in 2018. ... In May last year, approval for Skyrizi was filed in Japan for plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic

Lynparza could soon add first line ovarian use in Europe

The recommendation is based on the SOLO-1 trial in first-line BRCA-mutant ovarian cancer, with similar approvals expected soon in Japan and China, with US approval already secured.

Oncology drives AstraZeneca, Genzyme boosts Sanofi

AZ confirmed it will continue to drive oncology advancements, citing its recent partnership with Japan-based pharma group Daiichi Sankyo.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]